Medical Condition News

RSS

RGS proteins play an essential role in night blindness

In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified several proteins that help regulate cells' response to light-and the development of night blindness, a rare disease that abolishes the ability to see in dim light.

12 Jun 2012

Study shows how ruthenium-based drugs may be more effective at fighting cancer cells

A new study by University of Kentucky researchers shows how light and strained ruthenium-based drugs may be more effective at fighting cancer cells and less toxic to healthy cells than a similar and widely used drug.

12 Jun 2012

Researcher uncovers link between pro athlete's longevity and sleepiness

Coaches, owners and fantasy-league traders take note: Sleep researcher W. Christopher Winter, MD, has uncovered a link between a pro athlete's longevity and the degree of sleepiness experienced in the daytime.

12 Jun 2012

RVO advances PresbyLens into final phase of trial for treatment of presbyopia

ReVision Optics, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, announces the advancement of its proprietary product PresbyLens into the final phase of its U.S. clinical trial under an Investigational Device Exemption

12 Jun 2012

Individuals on statins more likely to experience fatigue with exertion

In a study of more than 1,000 adults, researchers at the University of California, San Diego, found that individuals taking cholesterol-lowering statin drugs are more likely than non-users to experience decreased energy, fatigue upon exertion, or both. The researchers suggest that these findings should be taken into account by doctors when weighing risk versus benefit in prescribing statins.

12 Jun 2012

MVP receives European patent for PEG conjugates of interferon-beta-1b to treat MS

Mountain View Pharmaceuticals, Inc. announced its receipt of European Patent No. 1 667 708 B1, titled "Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency."

12 Jun 2012

FDA clears MEVION S250 Proton Therapy System

Mevion Medical Systems, Inc., a radiation therapy company dedicated to advancing the treatment of cancer, announced today that it has received FDA 510(k) clearance for its MEVION S250 Proton Therapy System.

11 Jun 2012

Mutation responsible for rare, hereditary motor neuron disease disrupts vital links

Studying how nerve cells send and receive messages, Johns Hopkins scientists have discovered new ways that genetic mutations can disrupt functions in neurons and lead to neurodegenerative disease, including amyotrophic lateral sclerosis (ALS).

11 Jun 2012

New easy-to-use Bayer blood glucose monitoring system

A new blood glucose monitoring (BGM) system from Bayer, the CONTOUR Next EZ meter and CONTOUR Next test strips, proved easy to use and highly accurate in the hands of intended users -- patients and their healthcare professionals (HCPs) - according to a clinical study presented at the American Diabetes Association 72nd Scientific Sessions in Philadelphia, PA.

11 Jun 2012

Theramine may reduce chronic low back pain

Physician Therapeutics, Inc., a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, published results from a clinical trial of the company's proprietary medical food Theramine.

11 Jun 2012

Cardinal Health to open three new cyclotrons across the US

At the Society of Nuclear Medicine's 59th Annual Meeting in Miami Beach, Fla., June 9-12, Cardinal Health today announced that it plans to open three new cyclotrons across the United States, further expanding its nationwide capability to manufacture molecular imaging drugs that aid in the early diagnosis, monitoring and treatment of cancer, neurological disorders and heart disease.

11 Jun 2012

Higher quality bone from stem cells

UCLA stem cell scientists purified a subset of stem cells found in fat tissue and made from them bone that was formed faster and was of higher quality than bone grown using traditional methods, a finding that may one day eliminate the need for painful bone grafts that use material taken from the patient during invasive procedures.

11 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012

Cyberonics, Imricor enter agreement to develop MRI compatible leads for VNS Therapy System

Cyberonics, Inc. today announced that it has entered into an exclusive technology license agreement with Imricor Medical Systems, Inc. to develop Magnetic Resonance Imaging ("MRI") compatible leads for use with the VNS Therapy System (Vagus Nerve Stimulation).

11 Jun 2012

FDA accepts Avanir IND for AVP-923 to treat agitation in patients with AD

Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).

11 Jun 2012

Restoration of normal glucose regulation may prevent diabetes

People with pre-diabetes are significantly less likely to develop diabetes if their blood glucose levels are normalized in time, according to new research by the Colorado School of Public Health and the University of Colorado School of Medicine.

11 Jun 2012

Adult fear of the dark may contribute to insomnia

A small study of Toronto college students is shedding light on a contributing factor of insomnia that might be hard to admit - an adult fear of the dark.

11 Jun 2012

Epo has performance-enhancing effect on brain, may help treat depression, schizophrenia

Sportsmen and women dope with the blood hormone Epo to enhance their performance. Researchers from the University of Zurich now discovered by animal testing that Epo has a performance-enhancing effect in the brain shortly after injection and not only after days by improving oxygen transport in blood. As Epo also increases motivation, it could be useful in treating depression.

11 Jun 2012

Popular low carbohydrate diet leads to increase in cholesterol levels

A 25 year study in Northern Sweden, published in BioMed Central's open access journal Nutrition Journal, is the first to show that a regional and national dietary intervention to reduce fat intake, decreased cholesterol levels, but a switch to the popular low carbohydrate diet was paralleled by in an increase in cholesterol levels.

11 Jun 2012

$27 million received to speed new treatments for disabling neurological disorder

The Johns Hopkins University School of Medicine has announced receipt of a five-year, $27 million gift earmarked to fast-track the development of therapies to treat tumors associated with neurofibromatosis type 1 (NF1), a common and often debilitating neurogenetic disorder that causes tumors called plexiform neurofibromas to grow on nerves anywhere in the body.

11 Jun 2012